Teijin Limited · TSE:3401
Teijin — Q3 FY2004 Earnings Presentation
22 slides from Teijin's earnings presentation, Feb 3, 2005
Slide 1: Flash Report: Result of 3Q & Outlook for FY04
Flash Report Result of 3Q & Outlook for FY04 Teijin Limited February 3, 2005
Slide 2: Outline of FY04 3Q results
1. Outline of FY04 3Q results 1. Outline of FY04 3Q results (Ybn) (1) Consolidated results for FY04 3Q (vs. FY03 3Q) Sales OP ¾ Increase in sales & substantial increase in OP Sales +9.4% 233.2 Operating income 213.2 +37.9% 200 +20.1 Ordinary income +77.9% Net income +224.8% ¾ Extraordinary gain & lo
Slide 3: Operating results (FY04 3Q)
1. Outline of FY04 3Q results ◆Operating results (FY04 3Q) FY03 FY04 Diff. *1 Substantial diff. (Ybn) 3Q 3Q Amount % Amount % Sales 213.2 233.2 +20.1 +9.4% 1.2 +21.2 +10.0% Operating income 10.8 14.9 +4.1 +37.9% 0.4 +4.5 +42.7% [Operating income ratio] 5.1% 6.4% +1.3% - Nonoperating item -3.7 -2.3 +
Slide 4: Financial position and summary of cash flows
1. Outline of FY04 3Q results 996.2 ◆Financial position (Ybn) Total assets 944.3 (Ybn) Sep 30, 04 Dec 31, 04 Diff. 924.0 914.5 912.2 Total assets 912.2 944.3 +32.1 870.0 Interest-bearing debts 347.8 341.3 -6.4 ・Temporarily increased in total assets due to exchange rate changes: +32.1Ybn (Incl. effec
Slide 5: Operating results (FY04 1Q-3Q)
1. Outline of FY04 3Q results ◆Operating results (FY04 1Q-3Q) FY03 FY04 Diff. *1 Substantial diff. (Ybn) 1Q-3Q 1Q-3Q Amount % Amount % Sales 656.7 667.1 +10.4 +1.6% 34.4 +44.8 +7.2% Operating income 26.3 38.1 +11.9 +45.2% 3.8 +15.7 +69.7% [Operating income ratio] 4.0% 5.7% +1.7% - *1. Impact of with
Slide 6: Operating Results by Segment for FY04 3Q
1. Outline of FY04 3Q results (2) Operating Results by Segment for FY04 3Q (vs. FY03 3Q) ◆FY04 3Q Sales Operating income FY03 FY04 Diff. % FY03 FY04 Diff. % (Ybn) 3Q 3Q 3Q 3Q Synthetic Fibers 61.1 708 +9.7 +16% 2.2 3.1 +1.0 +46% Films & Plastics 48.3 55.5 +7.2 +15% 0.9 4.9 +4.0 +430% Pharma. & H. H.
Slide 7: FY04 1Q-3Q segment results
1. Outline of FY04 3Q results ◆FY04 1Q-3Q Sales Operating income FY03 FY04 Diff. % FY03 FY04 Diff. % (Ybn) 1Q-3Q 1Q-3Q 1Q-3Q 1Q-3Q Synthetic Fibers 181.1 204.0 +22.9 +13% 5.1 9.0 +3.9 +77% Films & Plastics 140.3 157.2 +16.9 +12% 2.2 12.4 +10.1 +455% Pharma. & H. H. C. 72.2 73.7 +1.5 +2% 14.6 15.4 +0
Slide 8: Synthetic Fibers: increases in sales and OP
1. Outline of FY04 3Q results ◆Operating results for FY04 3Q by segment a. Synthetic Fibers : ◆Operating results Increases in sales & OP ◇ Apparel: Increase in sales & reducing deficit to Sales OP barely break even (Ybn) ◇Industrial: Increases in sales & OP 204.0 20 ◆Summary & Actions for FY04 3Q 20
Slide 9: Films & Plastics: increase in sales, substantial increase in OP
1. Outline of FY04 3Q results b. Films & Plastics: Increase in sales & ◆Operating results substantial increase in OP ◇Films: Increase in sales & Sales OP substantial increase in OP (Ybn) ◇Plastics: Substantial increases in sales & OP 157.2 20 ◆Summary & Actions for FY04 3Q 140.3 ◇Films: Whole bar: 1
Slide 10: Pharma. & H. H. C.: unchanged sales, decrease in OP
1. Outline of FY04 3Q results c. Pharma. & H. H. C.: Unchanged in ◆Operating results sales & decrease in OP Sales OP ◇Pharma. & H. H. C.: Decrease in OP due to an increase in SGA (Ybn) expenses for an increase in MRs, etc. despite increases in both sales volume & rental volume 73.7 30 72.2 ◆Summary
Slide 11: Trading & Retail: increase in sales, unchanged OP
1. Outline of FY04 3Q results d. Trading & Retail: Increase in sales & unchanged in OP ◆Operating results Sales OP (Ybn) ◇ Trading : Increases in sales & OP 10.0 ◇Retail : Decreases in sales & OP 193.8 200 191.2 Whole bar: 1Q-3Q ◆Summary & Actions for FY04 3Q +1.4% 3Q ◇Trading: 150 - Strived to incr
Slide 12: IT & New products, etc.
1. Outline of FY04 3Q results e. IT & New products, etc.: Increase in sales & slight decrease in OP Sales OP ◆Operating results ◇IT： Increases in sales& OP 38.5 ◇New products, etc.: Increase in sales & 40 4.0 +13.2% (Ybn) decrease in OP - Increase in sales by transfer of Machinery & 34.0 Whole bar:
Slide 13: Outlook for FY04: Movement of Results
2. Outlook for FY04 2. Outlook for FY04 2H OP Sales for a year Previous Outlook* (Ybn) (1) Movement of Results 1H OP 900.0 OP Previous Sales 910.0 Outlook* 900 890.4 874.6 49.0 49.0 50 800 2H 38.7 25.8 40 700 35.3 2H 30 2H 23.3 600 20.1 20 1H 500 1H 1H 23.2 10 15.2 15.4 400 0 FY02 Actual FY03 Actual
Slide 14: Summary of Outlook for FY04
2. Outlook for FY04 (2) Summary of Outlook for FY04 FY03 FY04 Diff. FY03 Substantial diff. FY04 Revised Previous Actual Outlook Amount % *1 Amount % Outlook* (Ybn) Sales 874.6 910.0 +35.4 +4.1% 34.8 +70.2 +8.4% 900.0 Operating income 38.7 49.0 +10.3 +26.5% 3.5 +13.8 +39.1% 49.0 [Operating income rat
Slide 15: Outlook by segment
2. Outlook for FY04 (3) Outlook by segment Operating income Sales Operating income ratio FY04 FY04 FY04 FY03 FY03 FY03 Revised Diff. Revised Diff. Revised Actual Actual Actual Outlook Outlook Outlook (Ybn) Synthetic Fibers 247.5 275.0 +27.5 9.1 10.5 +1.4 3.7% 3.8% Films & Plastics 186.5 220.0 +33.5
Slide 16: Financial Highlight
2. Outlook for FY04 (4) Financial Highlight FY04 FY04 FY01 FY02 FY03 Previous Revised Actual Actual Actual Outlook* Outlook ROA : Operating income/ Total assets 2.7% 3.3% 4.0% 5.5% 5.5% ROE : Net income/ Shareholders’ equity 0.3% - 3.0% 4.4% 4.4% Operating income/ Net sales 3.2% 4.0% 4.4% 5.4% 5.4%
Slide 17: Disclaimer Regarding Forward-looking Statements
Disclaimer Regarding Forward-looking Statements Any statements in this document, other than those of historical fact, are forward-looking statements about the future performance of Teijin and its Group companies, which are based on management’s assumptions and beliefs in light of information current
Slide 18: Overview of Main Subsidiaries
(Supplementary Information) Overview of Main Subsidiaries for FY04 3Q & 1Q-3Q 3Q 1Q-3Q Sales OP Sales OP (Ybn) FY03 FY04 FY03 FY04 FY03 FY04 FY03 FY04 Teijin Fibers 25.1 33.1 -0.6 -0.1 78.9 90.4 -1.1 0.0 Synthetic Fibers 3 fiber companies in Southeast Asia 14.6 16.1 0.2 0.2 40.7 45.1 0.0 0.6 Aramid
Slide 19: Pharmaceutical Pipelines
(Supplementary Information) ◆Pharmaceutical Pipelines Phase of Clinical Trials Area Phase I / II Phase III Filed Approved/New launch Bone & joint Bonalon diseases (Weekly dose) TBN-15 Rhinocort BTR-15 (New type inhalator, (New steroid, Respiratory (Inhaled steroid for allergic rhinitis) allergic rhi
Slide 20: Balance sheet
(Supplementary Information) ◆Balance sheet Sep 30, Dec 31, (Ybn) Diff. Comments 04 04 Increase in trade notes & accounts receivable for seasonal factors & rising sales (+15.4) Current assets 364.6 389.3 +24.7 Increase in inventories for seasonal factors & soaring raw materials prices and fuel costs
Slide 21: Comparison with the previous outlook for FY04
(Supplementary Information) ◆Comparison with the previous outlook for FY04 FY04 FY04 Previous Revised Previous Revised Diff. Diff. (Ybn) Outlook* Outlook (Ybn) Outlook Outlook Synthetic fibers 270.0 275.0 +5.0 Sales 900.0 910.0 +10.0 Films & Plastics 215.0 220.0 +5.0 Operating income 49.0 49.0 - Pha
Slide 22: Filing process of TMX-67
(Supplementary Information) ◆Filing process of TMX-67 In Japan, in the reviewing process after NDA, we saw an increasing likelihood of a delay of a few years in the timing of approval to manufacture TMX-67, because we believe that we need to proceed with additional clinical trials. This observation